Sell into strength in pharma, says Mizuho's Jared Holz

Summary of YouTube Video Transcript

Key Concepts: FDA, AI in drug discovery, organoids, preclinical laboratory services, drug development timelines, pharma stocks, loss of exclusivity, IRA (Inflation Reduction Act), drug pricing, tariffs.

Impact of FDA's Shift Away from Animal Models

• Main Point: The FDA's move away from animal models towards AI and computational models for drug testing will have a lasting impact on companies providing preclinical laboratory services.
• Analyst Perspective: Mizuho Healthcare Strategist Jared Holt believes companies like Charles River Laboratories, which rely on animal models, are susceptible to selling due to uncertainty surrounding the adoption of AI and organoids.
• Uncertainty: The transition creates uncertainty for companies in the near and medium term.

AI and Organoids in Drug Discovery

• AI Benefits: AI is expected to speed up drug discovery and reduce costs.
• Organoids Explained: Organoids are small, organ-like structures grown from stem cells that mimic the function of organs like the brain, kidney, or liver. They enable faster and safer testing compared to human trials.
• Cost and Time Reduction: While the exact reduction in drug development timelines and costs is uncertain, any improvement is viewed as positive, given the current long and expensive drug development process.
• Investor Frustration: The long period between concept and market has frustrated investors in biotech and pharma.

Pharma Stock Outlook

• Analyst Recommendation: Jared Holt maintains a "sell" recommendation on pharma stocks.
• Reasons for Negative Outlook:
  • Loss of Exclusivity: Expected loss of exclusivity for many drugs later in the decade.
  • IRA Impact: The Inflation Reduction Act's drug pricing provisions create downward pressure.
  • Government Pricing Dynamics: Potential for further government intervention in drug pricing.
  • Tariffs: Uncertainty surrounding the implementation and extent of tariffs.

Logical Connections

The video connects the FDA's shift away from animal models to the rise of AI and organoids, which in turn impacts the business models of preclinical service providers. This shift, combined with other factors like drug pricing regulations and potential tariffs, contributes to a negative outlook for pharma stocks.

Synthesis/Conclusion

The FDA's move towards AI and organoids in drug testing is expected to disrupt the preclinical laboratory services industry and potentially accelerate drug discovery. However, uncertainties surrounding the transition and other factors like drug pricing regulations contribute to a negative outlook for pharma stocks. The analyst suggests that even a modest reduction in drug development time and cost would be a positive development, given the current state of the industry.